Egfr

Edit

J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research

PR Newswire 12 Feb 2026

EGFR-mutant NSCLC is driven by aberrant activation of EGFR signaling, and while EGFR-targeted therapies have dramatically improved outcomes over the past decade, acquired resistance remains inevitable for most, if not all patients.

Edit

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

PR Newswire 11 Feb 2026

EGFR-NSCLC Market Summary The market size for EGFR-NSCLC was found to be USD 6 billion in the leading markets in 2024 ... The total number of incident cases of EGFR-NSCLC in the leading market was nearly 117,000 in 2024 ... What is EGFR-NSCLC?.

Edit

EGFR + NSCLC Clinical Trial Pipeline Expands as 25+ Companies Driving Innovation in the Therapeutics ...

GetNews 09 Feb 2026

Inactive Products EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Companies EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Products EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Unmet Needs ...

Edit

Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients

PR Newswire 22 Jan 2026

... HT-001 in cancer patients receiving EGFR inhibitor therapy ... EGFR inhibitors are cornerstone therapies across multiple major cancer indications, including lung, colorectal, and head-and-neck cancers.

Edit

HANSOH PHARMA | AMEILE’S FIFTH INDICATION FOR “TARGETED THERAPY PLUS CHEMOTHERAPY” APPROVED, MARKING FULL-COURSE COVERAGE OF CHINA’S ORIGINAL THIRD-GENERATION EGFR-TKI (Hansoh Pharmaceutical Group Co Ltd)

Public Technologies 12 Jan 2026

AMEILE'S FIFTH INDICATION FOR "TARGETED THERAPY PLUS CHEMOTHERAPY" APPROVED, MARKING FULL-COURSE COVERAGE OF CHINA'S ORIGINAL THIRD-GENERATION EGFR-TKI ... Ameile is the first original third-generation EGFR-TKI innovative drug in China.

Edit

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

Nasdaq Globe Newswire 08 Jan 2026

- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated Q3 2026 – ... .

Edit

EGFR Inhibitors-Induced Skin Disorders Market Size in the 7MM is expected to increase at a ...

GetNews 08 Jan 2026

Discover Key Insights into the EGFR Inhibitors-Induced Skin Disorders Market with DelveInsight's In-Depth Report @ ... Nearly 20% of patients are affected with EGFR mutation in NSCLC ... EGFR Inhibitors-Induced Skin Disorders Emerging Drugs LUT014.

Edit

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

PR Newswire 18 Dec 2025

... targeted therapy for patients with EGFR+ mNSCLC ... Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC – Final Overall Survival from MARIPOSA [ELCC abstract #40].

Edit

Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma (Glenmark Pharmaceuticals Limited)

Public Technologies 16 Dec 2025

) Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma ... our ability to serve patients with EGFR-mutated lung cancer.

Edit

‘I am 74; recent blood report shows my kidney function (eGFR) as 53. How can I bring it to a normal level > 59?’

Indian Express 11 Dec 2025

Get kidney tests every 6-12 months .

Edit

RYBREVANT®▼(amivantamab) in combination with carboplatin and pemetrexed is accepted for use within NHS Scotland as a first-line treatment for adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations

Pharmiweb 09 Dec 2025

“EGFR+ UK is delighted that the Scottish Medicines Consortium has approved amivantamab with chemotherapy for eligible patients in Scotland diagnosed with EGFR Exon 20 insertion mutations NSCLC,” said Prof.

Edit

ORIC� Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 ...

Nasdaq Globe Newswire 03 Dec 2025

Company to host a conference call and webcast on Saturday, December 6, 2025, at 8.00 pm ET. Company to host a conference call and webcast on Saturday, December 6, 2025, at 8.00 pm ET ... .

Edit

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR

Enid News & Eagle 03 Dec 2025

SOUTH SAN FRANCISCO and SAN DIEGO, Dec ... (Nasdaq.

Edit

‘I am 52, not diabetic, BP 130\/90 but my creatinine is 1.35 and eGFR 55. What do I do to stop further deterioration? My weight is 90 kg’

Indian Express 25 Nov 2025

Check important metabolic markers ... .

Edit

BioDlink and Lepu Biopharma Celebrate Successful Launch of the World's First EGFR-Targeting ADC Drug, Marking ...

The Eagle-Tribune 21 Nov 2025

BioDlink and Lepu Biopharma celebrated the launch of MEIYOUHENG®, ...

Podcasts:

Latest News for: egfr

J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

EGFR + NSCLC Clinical Trial Pipeline Expands as 25+ Companies Driving Innovation in the Therapeutics ...

Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients

HANSOH PHARMA | AMEILE’S FIFTH INDICATION FOR “TARGETED THERAPY PLUS CHEMOTHERAPY” APPROVED, MARKING FULL-COURSE COVERAGE OF CHINA’S ORIGINAL THIRD-GENERATION EGFR-TKI (Hansoh Pharmaceutical Group Co Ltd)

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

EGFR Inhibitors-Induced Skin Disorders Market Size in the 7MM is expected to increase at a ...

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma (Glenmark Pharmaceuticals Limited)

‘I am 74; recent blood report shows my kidney function (eGFR) as 53. How can I bring it to a normal level > 59?’

RYBREVANT®▼(amivantamab) in combination with carboplatin and pemetrexed is accepted for use within NHS Scotland as a first-line treatment for adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations

ORIC� Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 ...

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR

‘I am 52, not diabetic, BP 130\/90 but my creatinine is 1.35 and eGFR 55. What do I do to stop further deterioration? My weight is 90 kg’

BioDlink and Lepu Biopharma Celebrate Successful Launch of the World's First EGFR-Targeting ADC Drug, Marking ...

Article Search

EXPLORE WN.com